American Century Companies Inc. Has $5.52 Million Stock Holdings in Takeda Pharmaceutical Co. $TAK

American Century Companies Inc. grew its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 12.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 357,029 shares of the company’s stock after acquiring an additional 40,821 shares during the period. American Century Companies Inc.’s holdings in Takeda Pharmaceutical were worth $5,520,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Evelyn Partners Investment Management LLP lifted its stake in shares of Takeda Pharmaceutical by 163.4% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock valued at $39,000 after purchasing an additional 1,560 shares during the last quarter. NewSquare Capital LLC increased its position in Takeda Pharmaceutical by 182.4% during the second quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock worth $53,000 after buying an additional 2,229 shares during the last quarter. MAI Capital Management raised its holdings in Takeda Pharmaceutical by 212.4% during the second quarter. MAI Capital Management now owns 5,177 shares of the company’s stock valued at $80,000 after buying an additional 3,520 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Takeda Pharmaceutical by 21.7% during the second quarter. Farther Finance Advisors LLC now owns 5,623 shares of the company’s stock valued at $87,000 after buying an additional 1,003 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Takeda Pharmaceutical in the first quarter worth about $125,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.7%

Shares of TAK stock opened at $14.18 on Friday. The firm has a market capitalization of $45.10 billion, a P/E ratio of 177.19 and a beta of 0.04. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.69. The firm’s fifty day simple moving average is $14.11 and its 200 day simple moving average is $14.62. The company has a current ratio of 1.37, a quick ratio of 0.76 and a debt-to-equity ratio of 0.61.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.44. The company had revenue of $7.30 billion for the quarter, compared to analyst estimates of $8.01 billion. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TAK shares. Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 1st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.